A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2 - PubMed (original) (raw)
Affiliations
- PMID: 8622639
A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2
Z H Song et al. Mol Pharmacol. 1996 May.
Abstract
Lys192 in the third transmembrane domain of the human CB1 cannabinoid receptor was converted to an alanine to study its role in receptor recognition and activation by agonists. HU-210, CP-55940, WIN55212-2, and anandamide, four cannabinoid agonists with distinct chemical structures, were used to characterize the wild-type and the mutant receptors. In human embryonal kidney 293 cells stably expressing the wild-type receptor, specific binding to [3H]WIN55212-2 and inhibition of cAMP accumulation by cannabinoid agonists were demonstrated, with different ligands exhibiting the expected rank orders of potency and stereoselectivity in competition binding and functional assays. In cells expressing the mutant receptor, the binding affinity of the receptor for [3H]WIN55212-2 was only slightly affected (the Kd for the mutant receptor was twice that of the wild-type), and the ability of WIN55212-2 to inhibit cAMP accumulation was unchanged. However, HU-210, CP-55940, and anandamide were unable to compete for [3H]WIN55212-2 binding to the mutant receptor. In addition, the potencies of HU-210, CP-55940, and anandamide in inhibiting cAMP accumulation were reduced by > 100-fold. These results demonstrate that Lys192 is critical for receptor binding by HU-210, CP-55940, and anandamide. Because Lys192 is not important for receptor binding and activation by WIN55212-2, WIN55212-2 must interact with the cannabinoid receptor through at least one point of interaction that is distinct from those of the three other agonists.
Similar articles
- Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.
Breivogel CS, Griffin G, Di Marzo V, Martin BR. Breivogel CS, et al. Mol Pharmacol. 2001 Jul;60(1):155-63. Mol Pharmacol. 2001. PMID: 11408610 - Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1.
Chin CN, Lucas-Lenard J, Abadji V, Kendall DA. Chin CN, et al. J Neurochem. 1998 Jan;70(1):366-73. doi: 10.1046/j.1471-4159.1998.70010366.x. J Neurochem. 1998. PMID: 9422383 - Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC, Wright JL, McPartland JM, Tyndall JD. Ashton JC, et al. Curr Med Chem. 2008;15(14):1428-43. doi: 10.2174/092986708784567716. Curr Med Chem. 2008. PMID: 18537620 Review.
Cited by
- The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
Hruba L, McMahon LR. Hruba L, et al. Eur J Pharmacol. 2014 Mar 15;727:35-42. doi: 10.1016/j.ejphar.2014.01.041. Epub 2014 Jan 30. Eur J Pharmacol. 2014. PMID: 24486701 Free PMC article. - Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes.
Navarro G, Varani K, Reyes-Resina I, Sánchez de Medina V, Rivas-Santisteban R, Sánchez-Carnerero Callado C, Vincenzi F, Casano S, Ferreiro-Vera C, Canela EI, Borea PA, Nadal X, Franco R. Navarro G, et al. Front Pharmacol. 2018 Jun 21;9:632. doi: 10.3389/fphar.2018.00632. eCollection 2018. Front Pharmacol. 2018. PMID: 29977202 Free PMC article. - Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization.
Ahn KH, Bertalovitz AC, Mierke DF, Kendall DA. Ahn KH, et al. Mol Pharmacol. 2009 Oct;76(4):833-42. doi: 10.1124/mol.109.057356. Epub 2009 Jul 30. Mol Pharmacol. 2009. PMID: 19643997 Free PMC article. - CB1 and CB2 Receptor Pharmacology.
Howlett AC, Abood ME. Howlett AC, et al. Adv Pharmacol. 2017;80:169-206. doi: 10.1016/bs.apha.2017.03.007. Epub 2017 Jun 12. Adv Pharmacol. 2017. PMID: 28826534 Free PMC article. Review. - Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
Cawston EE, Redmond WJ, Breen CM, Grimsey NL, Connor M, Glass M. Cawston EE, et al. Br J Pharmacol. 2013 Oct;170(4):893-907. doi: 10.1111/bph.12329. Br J Pharmacol. 2013. PMID: 23937487 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Miscellaneous